Published in J Clin Microbiol on August 01, 2000
Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun (2004) 3.29
Detecting bacteria and determining their susceptibility to antibiotics by stochastic confinement in nanoliter droplets using plug-based microfluidics. Lab Chip (2008) 2.11
Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun (2005) 1.05
Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin Diagn Lab Immunol (2004) 1.03
Fluorescent multivalent opsonophagocytic assay for measurement of functional antibodies to Streptococcus pneumoniae. Clin Diagn Lab Immunol (2005) 0.91
Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity. Clin Diagn Lab Immunol (2002) 0.87
Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis. Clin Vaccine Immunol (2011) 0.81
A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model. Infect Immun (2002) 0.78
Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay. Clin Diagn Lab Immunol (2002) 0.76
The Contribution of High-Order Metabolic Interactions to the Global Activity of a Four-Species Microbial Community. PLoS Comput Biol (2016) 0.75
Development of a high-throughput method to evaluate serum bactericidal activity using bacterial ATP measurement as survival readout. PLoS One (2017) 0.75
NEISSERIA GONORRHOEAE. I. VIRULENCE GENETICALLY LINKED TO CLONAL VARIATION. J Bacteriol (1963) 45.03
Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med (1969) 13.87
Growth Requirements of the Meningococcus. J Bacteriol (1942) 13.07
A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods (1994) 5.34
Classification of Neisseria meningitidis group B into distinct serotypes. I. Serological typing by a microbactericidal method. Infect Immun (1972) 4.96
Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol (1997) 4.65
Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) (1984) 4.62
INVESTIGATIONS OF MENINGOCOCCAL INFECTION. III. THE BACTERICIDAL ACTION OF NORMAL AND IMMUNE SERA FOR THE MENINGOCOCCUS. J Clin Invest (1943) 4.04
Infectious diseases associated with complement deficiencies. Clin Microbiol Rev (1991) 4.01
Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J Clin Microbiol (1995) 3.60
Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med (1978) 2.85
Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun (1983) 2.83
Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun (1995) 2.44
Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis (1998) 2.11
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine (1995) 2.06
Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun (1994) 1.96
A new fluorometric assay for cytotoxicity measurements in-vitro. Int J Oncol (1993) 1.96
Biologic activities of antibody to a peptidoglycan-associated lipoprotein of Haemophilus influenzae against multiple clinical isolates of H. influenzae type b. Infect Immun (1987) 1.82
Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine (1993) 1.75
Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann (1991) 1.68
Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am Biotechnol Lab (1993) 1.66
Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolysaccharide is not sialylated. Mol Microbiol (1992) 1.66
Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun (1996) 1.54
Reliability of two novel methods, Alamar and E test, for detection of methicillin-resistant Staphylococcus aureus. J Clin Microbiol (1993) 1.48
Complement-mediated bactericidal activity of human antibodies to poly alpha 2-->8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J Infect Dis (1995) 1.41
Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol (1988) 1.34
Complement-mediated bacterial killing assays. Methods Enzymol (1994) 1.24
Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potential. Vaccine (1995) 1.21
Human bactericidal antibody response to meningococcal outer membrane protein vaccines. Antonie Van Leeuwenhoek (1987) 1.13
A bactericidal monoclonal antibody specific for the lipooligosaccharide of Bordetella pertussis reduces colonization of the respiratory tract of mice after aerosol infection with B. pertussis. Infect Immun (1992) 1.10
Humoral immune responses to Neisseria meningitidis in children. Infect Immun (1999) 1.08
Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann (1991) 1.02
Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies. NIPH Ann (1991) 0.96
Recurrent meningococcal infections associated with a functional deficiency of the C8 component of human complement. Clin Exp Immunol (1980) 0.94
Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J Immunol Methods (1996) 0.87
[Immune bacteriolysis reaction in the assessment of immunological effectiveness of serogroup B meningococcal vaccine]. Klin Lab Diagn (1995) 0.77